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To assess the effect and toxicity of hypotonic cisplatin treatment (HPT) consisting of the intrapleural administration of cisplatin in
distilled water for malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). Non-small-cell lung cancer patients
with cytologically proven and previously untreated malignant pleural effusion were enrolled into this study. Firstly, the lung was fully
re-expanded by a tube thoracostomy, and then 25mg cisplatin in 500ml of distilled water was instilled through a chest tube and then
the tube was clamped. After 1h, the tube was declamped and allowed to drain. The chest tube was removed when the pleural
effusion volume decreased to 200ml or less per day. A complete response (CR) was considered to occur when the pleural effusion
disappeared. A partial response (PR) was determined to occur when the volume of pleural effusion remained under 1
4 of hemithorax.
The response at 4 weeks was evaluated by an extramural review. Out of 84 patients enrolled from February 1998 to August 2002,
80 patients were eligible and analysed in the present study. The toxicity of HPT was acceptable. Neither a haematological toxicity of
any grade nor grade 4 nonhaematological toxicity was observed. Grade 3 nonhaematological toxicities were observed, including
nausea (4%), vomiting (3%), pyothorax (1%) and dyspnoea (1%). The median time of drainage from HTP was 4 days. Twenty-seven
(34%) and 39 (49%) patients achieved CR and PR, respectively, for an overall response rate of 83% (95% confidence interval, 74–
91%). The median duration of the response was 206 days. The median survival time of all patients was 239 days. Hypotonic cisplatin
treatment for malignant pleural effusion of NSCLC is therefore considered to be feasible and effective. A phase III study of HPT is
thus warranted.
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Malignant pleural effusion is considered to be the first clinical
manifestation of malignancy as well as the first sign of recurrent
cancer. Among the various kinds of malignancies, lung cancer
is the leading cause of malignant effusion (Chernow and Sahn,
1977; Shan, 1987). The standard treatment for a patient with a
symptomatic malignant pleural effusion due to non-small-cell lung
cancer (NSCLC), whose life expectancy is not too short, is
considered to be a tube thoracotomy with subsequent pleurodesis
(Ruckdeschel et al, 1991; Walker-Renard et al, 1994).
Ichinose et al (1997) reported that intraoperative intrapleural
treatment using hypotonic cisplatin solution (cisplatin solution
diluted by distilled water) effectively controlled malignant pleural
effusion and/or pleural dissemination found at thoracotomy in
NSCLC patients. According to their experimental data, hypotonic
cisplatin solution demonstrated a significantly greater antitumour
activity than either isotonic cisplatin or distilled water alone
(Ichinose et al, 1993).
Ushijima et al (1997) applied this hypotonic cisplatin treatment
(HPT) consisting of the intrapleural administration of cisplatin in
distilled water after tube thoracostomy to treat malignant pleural
effusion due to NSCLC and gastric cancer, and reported successful
results in several patients. A multi-institutional phase II trial was
thus conducted to assess the effect and toxicity of HPT for
malignant pleural effusion due to NSCLC.
PATIENTS AND METHODS
Patient eligibility
The patients were eligible for this phase II trial if they had
cytologically proven and previously untreated malignant pleural
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seffusion of NSCLC, which had either not yet been treated or had
been treated 4 weeks or more before enrolment. All participants
were required to be under 80 and 80 year of age, with a leucocyte
count of p4000ml
1, a platelet count of 4100000ml
1, a serum
bilirubin level p1.5mgdl
1, a normal creatinine level and serum
glutamic oxaloacetic transaminase/glutamic pyruvic transaminase
levels of no more than twice the upper limit of normal. The
patients were also required to have a sufficient re-expansion of the
lung after chest tube drainage and an Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of 0, 1 or 2
after drainage. The extent of re-expansion was re-assessed by an
extramural review committee. Systemic chemotherapy or radio-
therapy to the lung, mediastinum and pleura was not given for
4 weeks after HPT. This trial was approved by the institutional
review boards of each participating institution, and written
informed consent was obtained from all patients.
Treatment methods
The lung was fully expanded by a thoracostomy using a chest tube
with a double lumen, and then the patients were enrolled into the
trial via facsimile by the administration office of the Kyushu
Yamaguchi Thoracic Oncology Group in the National Kyushu
Cancer Center. First, premedications, intramuscular injection of
15mg of pentazocine and intrapleural administration of 10ml of
1% lidocaine were performed. Thereafter, 25mg of cisplatin in
500ml of distilled water was instilled through a chest tube. The
hypotonic cisplatin solution was prepared as follows: 50ml
cisplatin solution containing 25mg cisplatin was injected into
the bottle containing distilled water of 500ml. The chest tube was
clamped for 1h. The patients were then asked to change position
(supine and bilateral decubital) from time to time during the
treatment regimen, and then the tube was declamped and allowed
to drain under a negative pressure of 10–15cm H2O. When the
drainage effusion was less than 200ml a day, the chest tube was
removed. Any patient whose drainage effusion continued for over
2 weeks was withdrawn from the trial and was also judged to be a
nonresponder.
Evaluations
Toxicities were evaluated according to ECOG common toxicities
criteria (Oken et al, 1982).
The response to HPT was evaluated based on the findings of
posteroanterior and lateral chest radiographs 4 weeks after HPT.
The response criteria used were as follows: a complete response
(CR) when no pleural effusion was observed; a partial response
(PR) when pleural effusion was observed, but the level of effusion
was less than 25% of the long axis of the hemithorax; and no
response (NR) when effusion was larger than that defined by PR. A
chest radiograph in responding patients was taken at least every
month in order to monitor the condition of the controlled pleural
effusion. The response and duration of response were determined
by an extramural review committee.
A progression of effusion was defined as when pleural effusion
of more than 25% of the long axis of the hemithorax was observed
or tube drainage was needed. The effusion-progression-free
survival time was defined as the time from the enrolment until
the progression of effusion or death without a progression of
effusion. The overall survival was defined as the time from
enrolment until death from any cause.
Statistical analysis
The primary end point of the study was the overall response rate
including CR and PR. Based on the assumption that a response
rate of higher than 75% would warrant further investigation of this
treatment, and that a rate below 60% would make such an
investigation unnecessary, a total sample size of 62 patients was
required with an alpha error of 0.05 and a beta error of 0.20, using
the mini-max two-stage sequential design by Simon. The first stage
of the study required 30 patients, and if at least 18 responses were
observed, then a second stage required 32 patients would be
conducted. Since ineligible patients would be included, the accrual
of at least 70 patients was thus planned.
RESULTS
Patient characteristics
Eighty-four patients were enrolled into this trial from February
1998 to August 2002. However, four patients were later judged to
be ineligible: two patients had malignant pleural effusion due to
either parotid gland cancer or uterus cancer, one patient had
bilateral malignant effusion and one patient had a poor PS who
had no chest X-ray film in the standing position. As a result, 80
patients were eligible and thus were analysed in the present study.
As shown in Table 1, they included 40 men and 40 women with a
median age of 67 years. Most patients had an ECOG PS of 0 or 1
and a histology of adenocarcinoma. In addition, 73% of the
patients had received no prior therapy. Although the extent of a re-
expansion of the lung after tube thoracotomy was judged to be
equivocal in four patients at an extramural review committee,
those patients were included in the analysis.
Adverse events
Neither the haematological toxicity of any grade nor of grade 4
nonhaematological toxicity was observed in all 80 eligible patients
(Table 2). Grade 3 nonhaematological toxicities were observed,
including nausea (4%), vomiting (3%), dyspnoea (1%) and
pyothorax (1%).
Table 1 Patient characteristics
Enrolled patients 84
Eligible patients 80
Gender
Male 40 (50%)
Female 40 (50%)
Age median (range) 67 (35–89)
ECOG performance status
0 24 (30%)
1 47 (59%)
2 9 (11%)
Stage
IIIB 35 (44%)
IV 45 (56%)
Histological type
Adenocarcinoma 77 (96%)
Squamous cell carcinoma 3 (4%)
Prior therapy
None 58 (73%)
Surgical resection only 7 (9%)
Chemotherapy or radiotherapy 10 (13%)
Surgical resection plus chemotherapy or radiotherapy 5 (6%)
Re-expansion of lung
Sufficient 76 (95%)
Equivocal 4 (5%)
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Among the 80 patients including one patient whose response was
not evaluable due to complications of pyothorax, 27 patients (34%)
had CR and 39 patients (49%) achieved PR with an overall
response rate of 83% (95% confidence interval 74–91%). There
were also 13 patients with NR. Two of these 13 patients were
withdrawn from the trial since their effusion could not be
controlled within 2 weeks after HPT. The median duration of
drainage after HPT in the responding patients was 2 days ranging
from 1 to 22 days. The median time of response was 206 days in 66
responding patients ranging 36–949 days.
Survival
The median follow-up period was 1045 days (range, 424–2061
days). The median effusion-progression-free survival time and 1-
year effusion-progression-free survival rate of all 80 patients were
173 days and 31.8% (95% confidence interval, 22–42%). The
median survival time and the 1-year survival rate of all 80 patients
were 239 days and 39% (95% confidence interval, 28–49%) as
shown in Figure 1.
DISCUSSION
The agents administered intrapleurally for the management of
malignant pleural effusion were classified as either non-anticancer
or anticancer drugs. The non-anticancer drug had a sclerosing
agent that produces pleurodesis. The most frequently used agent is
talc in the United States (Hausheer and Yarbro, 1985), tetracycline
or doxycycline (Putnam et al, 1999) in the United Kingdom and
OK432, which is prepared from a substrain of Streptococcus
pyrogenes A3, in Japan (Saka et al, 1994). In a majority of cases,
talc is administered by pleural pourdage through thoracoscopy
using either local anaesthesia or general anaesthesia by the surgical
team. Although the response rate to thoracoscopic talc insertion is
reported to be over 90%, the requirement of thoracoscopy leads to
some limitations in the use of talc. In addition, the frequency of
severe chest pain induced by treatment with talc pleurodesis was
reported to be 17% (Hartman et al, 1993). On the other hand, no
such pain was observed in the 80 patients who received this
intrapleural HPT for malignant effusion due to NSCLC. The
intrapleural administration of the tetracycline or doxycycline was
reported to be effective for the control of malignant effusion.
However, it has recently become difficult to use tetracycline or
doxycycline since these have been withdrawn from the market in
1991 and 1997, respectively. The administration of OK432 in saline
solution is easily performed through a chest tube and it is reported
to control over 70% of malignant pleural effusion cases. However,
its usage is still limited to only Japan.
Although anticancer drugs administered intrapleurally for the
management of malignant pleural effusions are expected to have
both cytotoxic and sclerosing effects, the mechanism of action
for controlling effusion remains unclear. The results of etoposide
(Holoye et al, 1990), fluorouracil (Suhrland and Weisberger, 1965),
mitomycin-C (Luh et al, 1992) or doxorubicin (Desai and
Figueredo, 1979) investigated in various trials have not proven
to be sufficiently attractive and these agents are therefore not
presently in use. In a randomised trial comparing intrapleural
administration of bleomycin with intrapleural tetracycline, bleo-
mycin has been proven to be superior to tetracycline for the
management of malignant pleural effusion (Moffett and Ruck-
deschel, 1992). However, bleomycin has not been used extensively
due to its high expense. The Lung Cancer Study Group performed
a phase II trial of the intrapleural administration of combination
chemotherapy using cisplatin and cytarabine in 46 patients, of
whom about half had NSCLC (Rusch et al, 1991). Tohda et al
(1999) also performed a similar phase II trial using cisplatin plus
etoposide in 70 NSCLC patients. The overall response rate was
reported to be 49% in the former trial and 46% in the later trial. As
the criteria of the response and proportions of the disease in the
subjects vary between the different trials, an accurate comparison
of the results is difficult. However, the response rate reported in
Table 2 Nonhaematological toxicities
Grade 1 2 3 4
Nausea 21 11 3 (4%) 0
Vomiting 7 7 2 (3%) 0
Fever 11 0 0 0
Dyspnoea 5 2 1 (1%) 0
Chest pain 13 5 0 0
Infection 0 0 1 (1%) 0
0
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Overall survival
Median survival time = 239 days
1-year survival = 38.7% (95% CI, 28.1− 49.3)
Progression-free survival
Median PFS time = 173 days
1-year PFS = 31.8% (95% CI, 21.6 −  42.0)
Figure 1 Overall survival and progression-free survival. Each tick mark and bar represents a patient who is alive and the 95% confidence interval of the
survival rate, respectively.
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on the whole, inferior to that in the trials using a non-anticancer
agent.
In the present phase II trial of the intrapleural administration of
hypotonic cisplatin solution in 80 patients with NSCLC, the overall
response rate was 83%. The criteria of the response in this trial
were similar to those of the cisplatin-based intrapleural chemo-
therapy trials mentioned above. The main difference between the
previously reported intrapleural cisplatin-based chemotherapy and
our HPT is the use of isotonic saline in the former and distilled
water in the latter for a dilution of cisplatin, which itself is an
isotonic solution. Ichinose et al (1993) found that hypotonic
cisplatin solution whose cisplatin concentration and osmolarity
ranged between 5 and 50mgml
1 and between 2.8 and
28mOsml
1, respectively, had a significantly stronger antitumour
activity than either isotonic cisplatin or distilled water alone in an
in vitro experiment of short-time exposure ranging from 0.5 to
10min. In a prospective study in patients whose malignant pleural
effusion and/or pleural dissemination were found at thoracotomy,
intraoperative intrapleural HPT for 15min before the closure of
thorax prolonged the control of the pleural disease (Ichinose et al,
1997). In addition, a randomised phase III trial demonstrated the
intraoperative intrapleural HPT in resected NSCLC patients with
a positive intrapleural lavage cytology finding to significantly
decrease the occurrence of malignant effusion and/or pleural
dissemination after operation (Ichinose et al, 2002). The cisplatin
concentration (50mgml
1) and hypotonicity (28mOsml
1) were
the same as those in the present trial. The mechanism by which the
HPT shows an antitumour effect is considered to be as follows: (1)
distilled water itself has a direct cytotoxicity (Ichinose et al, 1993),
(2) tumour cells exposed to hypotonic cisplatin increase their
cellular cisplatin level since the cells become swollen by the
hypotonic solution (Ichinose et al, 1993) and (3) chloroaqua and
diaqua, formed by the hydrolysis of cisplatin in distilled water, are
also believed to be active antitumour agents (Rosenberg, 1978;
Sherman and Lippard, 1987).
The incidence of the toxicities seen in this study was
significantly lower than that in the cisplatin-based chemotherapy
trials. Grade 3 non-haematological toxicities were observed,
including nausea (4%), vomiting (3%), dyspnoea (1%) and
infection (1%) in the present trial, while 90% of the patients had
gastrointestinal toxicities including grade 3 and 49 and 9% of the
patients experienced haematologic toxicities of grades 1 plus 2
and that of grade 3, respectively, in the trial of the Lung Cancer
Study Group. Tohda et al (1999) reported a gastrointestinal
toxicity of grade 3 in 27% of the patients. The main reasons
for a different incidence of toxicities between the two trials and
our trial are considered to be due to the differences in intra-
pleural exposure time of the agent and the administered dosage
between trials: (1) the clamping time after the intrapleural
administration was only 1h in our trial compared to either 4 or
72h in the previous trials and (2) the dose of cisplatin
administered was 25mgbody
1 once or twice in our trial, while
it was 80 and 100mgm
2 in the previous trials. Regardless of
the administration of cisplatin with lower dosage as well as the
shorter treatment time, the response rate of the HPT, nevertheless,
seems to be superior to that of the previously reported
chemotherapy trials.
In addition, the overall survival and effusion-progression-free
survival curves are closely similar as shown in Figure 1. This
observation indicates that malignant pleural effusion was con-
trolled by HPT in most patients.
Although HPT is considered to be a feasible and active treatment
for malignant effusion due to NSCLC, further trials are called for.
The Japan Clinical Oncology Group (JCOG) conducted a
randomised phase II study for malignant pleural effusion due to
NSCLC, by comparing bleomycin, OK-432 and cisplatin plus
etoposide. We therefore intend to conduct a phase III study to
compare HPT with the best arm of the JCOG trial.
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